Hyperthermic Isolated Limb Perfusion With Tumor Necrosis Factor Is a Useful Therapy for Advanced Melanoma of the Limbs

This publication has 11 references indexed in Scilit:

• Randomized Multicenter Trial of Hyperthermic Isolated Limb Perfusion With Melphalan Alone Compared With Melphalan Plus Tumor Necrosis Factor: American College of Surgeons Oncology Group Trial Z0020
  Journal of Clinical Oncology, 2006
• Technology Insight: utility of TNF-α-based isolated limb perfusion to avoid amputation of irresectable tumors of the extremities
  Nature Clinical Practice Oncology, 2006
• One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit Metastases
  Annals of Surgery, 2004
• Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma Metastases
  Annals of Surgical Oncology, 2004
• Abstracts Accepted for Plenary & Parallel Sessions 55th Annual Cancer Symposium Society of Surgical Oncology March 14–17, 2002 Denver, CO
  Annals of Surgical Oncology, 2002
• Isolated Limb Perfusion
  Surgical Oncology Clinics of North America, 2001
• Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
  British Journal of Cancer, 2000
• Isolated limb perfusion with tumour necrosis factor-α and melphalan with or without interferon-γ; for the treatment of in-transit melanoma metastases
  Melanoma Research, 1999
• Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ
  Nature Medicine, 1998
• Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas
  Annals of Surgery, 1996